Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -$8.3 million.

  • RedHill Biopharma's Net Income towards Common Stockholders rose 231.03% to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 75.62%. This contributed to the annual value of -$8.3 million for FY2024, which is 134.57% down from last year.
  • Per RedHill Biopharma's latest filing, its Net Income towards Common Stockholders stood at -$8.3 million for FY2024, which was down 134.57% from $23.9 million recorded in FY2023.
  • RedHill Biopharma's Net Income towards Common Stockholders' 5-year high stood at $51.2 million during FY2020, with a 5-year trough of -$97.7 million in FY2021.
  • Its 3-year average for Net Income towards Common Stockholders is -$18.7 million, with a median of -$8.3 million in 2024.
  • As far as peak fluctuations go, RedHill Biopharma's Net Income towards Common Stockholders tumbled by 290.92% in 2021, and later spiked by 133.37% in 2023.
  • Over the past 5 years, RedHill Biopharma's Net Income towards Common Stockholders (Yearly) stood at $51.2 million in 2020, then plummeted by 290.92% to -$97.7 million in 2021, then grew by 26.68% to -$71.7 million in 2022, then spiked by 133.37% to $23.9 million in 2023, then crashed by 134.57% to -$8.3 million in 2024.